Literature DB >> 31453766

Left Ventricular Mass at MRI and Long-term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA).

Nadine Kawel-Boehm1, Richard Kronmal1, John Eng1, Aaron Folsom1, Gregory Burke1, J Jeffrey Carr1, Steven Shea1, João A C Lima1, David A Bluemke1.   

Abstract

Background Few data exist on the long-term risk prediction of elevated left ventricular (LV) mass quantified by MRI for cardiovascular (CV) events in a contemporary, ethnically diverse cohort. Purpose To assess the long-term impact of elevated LV mass on CV events in a prospective cohort study of a multiethnic population in relationship to risk factors and coronary artery calcium (CAC) score. Materials and Methods The Multi-Ethnic Study of Atherosclerosis, or MESA (ClinicalTrials.gov: NCT00005487), is an ongoing prospective multicenter population-based study in the United States. A total of 6814 participants (age range, 45-84 years) free of clinical CV disease at baseline were enrolled between 2000 and 2002. In 4988 participants (2613 [52.4%] women; mean age, 62 years ± 10.1 [standard deviation]) followed over 15 years for CV events, LV mass was derived from cardiac MRI at baseline enrollment by using semiautomated software at a central core laboratory. Cox proportional hazard models, Kaplan-Meier curves, and z scores were applied to assess the impact of LV hypertrophy. Results A total of 290 participants had hard coronary heart disease (CHD) events (207 myocardial infarctions [MIs], 95 CHD deaths), 57 had other CV disease-related deaths, and 215 had heart failure (HF). LV hypertrophy was an independent predictor of hard CHD events (hazard ratio [HR]: 2.7; 95% confidence interval [CI]: 1.9, 3.8), MI (HR: 2.8; 95% CI: 1.8, 4.0), CHD death (HR: 4.3; 95% CI: 2.5, 7.3), other CV death (HR: 7.5; 95% CI: 4.2, 13.5), and HF (HR: 5.4; 95% CI: 3.8, 7.5) (P < .001 for all end points). LV hypertrophy was a stronger predictor than CAC for CHD death, other CV death, and HF (z scores: 5.4 vs 3.4, 6.8 vs 2.4, and 9.7 vs 3.2 for LV hypertrophy vs CAC, respectively). Kaplan-Meier analysis demonstrated an increased risk of CV events in participants with LV hypertrophy, particularly after 5 years. Conclusion Elevated left ventricular mass was strongly associated with hard coronary heart disease events, other cardiovascular death, and heart failure over 15 years of follow-up, independent of traditional risk factors and coronary artery calcium score. © RSNA, 2019 See also the editorial by Hanneman in this issue.

Entities:  

Mesh:

Year:  2019        PMID: 31453766      PMCID: PMC6776886          DOI: 10.1148/radiol.2019182871

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   29.146


  38 in total

1.  Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas.

Authors:  Saul G Myerson; Hugh E Montgomery; Michael J World; Dudley J Pennell
Journal:  Hypertension       Date:  2002-11       Impact factor: 10.190

2.  The progression from hypertension to congestive heart failure.

Authors:  D Levy; M G Larson; R S Vasan; W B Kannel; K K Ho
Journal:  JAMA       Date:  1996 May 22-29       Impact factor: 56.272

3.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

4.  Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Chia-Ying Liu; Susan R Heckbert; Shenghan Lai; Bharath Ambale-Venkatesh; Mohammad R Ostovaneh; Robyn L McClelland; João A C Lima; David A Bluemke
Journal:  J Am Coll Cardiol       Date:  2017-12-26       Impact factor: 24.094

5.  Cardiovascular imaging for assessing cardiovascular risk in asymptomatic men versus women: the multi-ethnic study of atherosclerosis (MESA).

Authors:  Aditya Jain; Robyn L McClelland; Joseph F Polak; Steven Shea; Gregory L Burke; Diane E Bild; Karol E Watson; Matthew J Budoff; Kiang Liu; Wendy S Post; Aaron R Folsom; João A C Lima; David A Bluemke
Journal:  Circ Cardiovasc Imaging       Date:  2010-11-10       Impact factor: 7.792

6.  The prognostic legacy of left ventricular hypertrophy: cumulative evidence after the MAVI study.

Authors:  Fabio Angeli; Gianpaolo Reboldi; Cristina Poltronieri; Elisa Stefanetti; Claudia Bartolini; Paolo Verdecchia
Journal:  J Hypertens       Date:  2015-11       Impact factor: 4.844

Review 7.  Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: a critical appraisal.

Authors:  Pentti M Rautaharju; Elsayed Z Soliman
Journal:  J Electrocardiol       Date:  2014-06-09       Impact factor: 1.438

8.  Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  Ann Intern Med       Date:  1989-01-15       Impact factor: 25.391

9.  Left ventricular mass and geometry and the risk of ischemic stroke.

Authors:  Marco R Di Tullio; Donna R Zwas; Ralph L Sacco; Robert R Sciacca; Shunichi Homma
Journal:  Stroke       Date:  2003-09-04       Impact factor: 7.914

10.  Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification.

Authors:  Lyndia C Brumback; Richard Kronmal; Susan R Heckbert; Hanyu Ni; W Gregory Hundley; João A Lima; David A Bluemke
Journal:  Int J Cardiovasc Imaging       Date:  2010-01-27       Impact factor: 2.357

View more
  16 in total

Review 1.  Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.

Authors:  Goran Koracevic; Milovan Stojanovic; Dragan Lovic; Marija Zdravkovic; Dejan Sakac
Journal:  J Hum Hypertens       Date:  2021-03-02       Impact factor: 3.012

2.  Left Ventricular Mass and Wall Thickness Measurements Using Echocardiography and Cardiac MRI in Patients with Fabry Disease: Clinical Significance of Discrepant Findings.

Authors:  Ciara O'Brien; Ian Britton; Gauri R Karur; Robert M Iwanochko; Chantal F Morel; Elsie T Nguyen; Paaladinesh Thavendiranathan; Anna Woo; Kate Hanneman
Journal:  Radiol Cardiothorac Imaging       Date:  2020-06-11

3.  Regional Strain Score as Prognostic Marker of Cardiovascular Events From the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Theo Pezel; David A Bluemke; Colin O Wu; João A C Lima; Bharath Ambale Venkatesh
Journal:  Front Cardiovasc Med       Date:  2022-05-13

4.  Left Atrioventricular Coupling Index to Predict Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Theo Pezel; Bharath Ambale Venkatesh; Yoko Kato; Henrique Doria De Vasconcellos; Susan R Heckbert; Colin O Wu; Wendy S Post; David A Bluemke; Alain Cohen-Solal; Patrick Henry; João A C Lima
Journal:  Front Cardiovasc Med       Date:  2021-09-01

Review 5.  Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials.

Authors:  Jian-Shu Chen; Ying Pei; Cai-E Li; Yin-Ning Li; Qiong-Ying Wang; Jing Yu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-11-15       Impact factor: 3.738

6.  Deep Learning to Predict Cardiac Magnetic Resonance-Derived Left Ventricular Mass and Hypertrophy From 12-Lead ECGs.

Authors:  Shaan Khurshid; Samuel Friedman; James P Pirruccello; Paolo Di Achille; Nathaniel Diamant; Christopher D Anderson; Patrick T Ellinor; Puneet Batra; Jennifer E Ho; Anthony A Philippakis; Steven A Lubitz
Journal:  Circ Cardiovasc Imaging       Date:  2021-06-15       Impact factor: 8.589

7.  Sex differences and the left ventricle: morphology matters.

Authors:  C Noel Bairey Merz; Michael D Nelson; Susan Cheng; Janet Wei
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-09-01       Impact factor: 9.130

Review 8.  19 F MRI Nanotheranostics for Cancer Management: Progress and Prospects.

Authors:  Yanan Li; Jing Cui; Chenlong Li; Huimin Zhou; Jun Chang; Omer Aras; Feifei An
Journal:  ChemMedChem       Date:  2022-01-12       Impact factor: 3.540

9.  Pericardial Fat and the Risk of Heart Failure.

Authors:  Satish Kenchaiah; Jingzhong Ding; J Jeffrey Carr; Matthew A Allison; Matthew J Budoff; Russell P Tracy; Gregory L Burke; Robyn L McClelland; Andrew E Arai; David A Bluemke
Journal:  J Am Coll Cardiol       Date:  2021-06-01       Impact factor: 27.203

10.  Diastolic dysfunction in people with HIV without known cardiovascular risk factors in Western Kenya.

Authors:  Bethel Woldu; Tecla M Temu; Nicholas Kirui; Bridgette Christopher; Samson Ndege; Wendy S Post; Jemima Kamano; Gerald S Bloomfield
Journal:  Open Heart       Date:  2022-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.